Molbio Diagnostics Shares List at 21% Premium

Molbio Diagnostics made a strong market debut on Monday, with shares listing at a 21% premium over the IPO price on both the NSE and BSE.

The company's successful listing follows a robust subscription phase, reflecting strong investor confidence in the diagnostic firm's growth prospects and market position.

Investors are now closely watching the stock's performance to see if it can sustain these gains amid broader market volatility and sector-specific headwinds.